Glenmark Pharmaceuticals. has filed a patent for a method to prepare virus-free antibody solutions from cultured cells. The process involves harvesting antibody material from transfected cells, then subjecting it to a virus inactivation treatment using a mixture of solvent and detergent. GlobalData’s report on Glenmark Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Glenmark Pharmaceuticals Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Glenmark Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Glenmark Pharmaceuticals's grant share as of January 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.

Method for preparing virus-inactivated antibody solution

Source: United States Patent and Trademark Office (USPTO). Credit: Glenmark Pharmaceuticals Ltd

A patent application (Publication Number: US20240002434A1) describes a method for preparing a virus-inactivated antibody solution. The method involves harvesting antibody material produced by transfected cells containing coding sequences of an antibody, subjecting the harvested material to a virus inactivation treatment using a mixture of solvent and detergent, and ensuring the harvested material is a clarified harvest. The harvested antibody material can be produced in non-human mammalian cells and may include monoclonal antibodies, including recombinant and multispecific antibodies. The specific concentrations of the solvent (TnBP) and detergents (Triton X-100, Polysorbate 80, Polysorbate 20) used in the virus inactivation treatment are outlined in the claims.

Furthermore, the patent application details a method for the production of a bulk drug substance involving various steps such as culturing host cells, harvesting the antibody-containing cell culture, subjecting the harvested material to viral inactivation, and subsequent purification processes including protein A chromatography, cation exchange chromatography, and virus nanofiltration. The final steps involve concentrating the solution, adding excipients to obtain the desired concentration, filtering the bulk drug substance, and filling it into sterile bags for freezing and storage. The concentrations of the detergents and solvents used in the viral inactivation process, as well as the specific purification steps, are clearly defined in the claims of the patent application.

To know more about GlobalData’s detailed insights on Glenmark Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies